Clinical Outcomes Between Direct Oral Anticoagulants Versus Vitamin K Antagonists in Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis

Pulmonary hypertension (PH) is a known chronic condition that can lead to increased morbidity and mortality. Patients who develop PH due to thromboembolic disease are catalogued as chronic thromboembolic pulmonary hypertension (CTEPH). Anticoagulation remains a topic of interest in these patients. PUBMED, EMBASE and COCHRANE databases were searched by two investigators until December 2023. Information was analyzed for all-cause mortality, venous thromboembolism and major bleeding. We included a total of 10 studies in this meta-analysis. Our pooled analysis demonstrated that DOACs were non-inferior in all-cause mortality [OR 0.88, 95% CI (0.48, 1.61)], venous thromboembolism [OR 1.00, 95% CI (0.50, 1.98)] and major bleeding [OR 0.78, 95% CI (0.43, 1.40)] when compared to VKAs. In conclusion, our meta-analysis supports the use of DOACs in patients with CTEPH. Further randomized trials are still needed to confirm our results in terms of safety and mortality